Marek Honczarenko Healthcare News

This is selected healthcare news for Marek Honczarenko, which is filed under People. There are 7 news items for this page. A press release filter page is also available for Marek Honczarenko.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
5/27/2020 AbbVie Presents New Data at the European E-Congress of Rheumatology (EULAR) 2020 Showcasing Depth of its Rheumatology Portfolio
... a leader in immunology for over two decades, AbbVie is dedicated to developing innovative therapies for patients living with debilitating, chronic immune-mediated conditions," said Marek Honczarenko MD, PhD, vice president, global immunology development, AbbVie. "The new research from across our portfolio presented at EULAR underscores our commitment to improving ...
PR Newswire
11/12/2019 New Positive Data for RINVOQ™ (upadacitinib) on Signs and Symptoms in Patients with Ankylosing Spondylitis Presented at 2019 ACR/ARP Annual Meeting
... the SELECT-AXIS 1 study show that RINVOQ was able to provide significant improvements to signs and symptoms for patients living with ankylosing spondylitis," said Marek Honczarenko, M.D., Ph.D., vice president, immunology development, AbbVie. "These data highlight AbbVie's commitment to discovering and developing additional therapies for patients living with rheumatic ...
PR Newswire
11/4/2019 AbbVie to Showcase Depth of Immunology Portfolio and Pipeline at the 2019 ACR/ARP Annual Meeting
... the latest research across our recently expanded rheumatology portfolio at this year's meeting, including data that further support our recent FDA approval of RINVOQ," said Marek Honczarenko , M.D., Ph.D., vice president, global immunology development, AbbVie. "New data being presented on upadacitinib, risankizumab and adalimumab across multiple rheumatic diseases will highlight ...
PR Newswire
11/4/2019 AbbVie to Showcase Depth of Immunology Portfolio and Pipeline at the 2019 ACR/ARP Annual Meeting
... the latest research across our recently expanded rheumatology portfolio at this year's meeting, including data that further support our recent FDA approval of RINVOQ," said Marek Honczarenko , M.D., Ph.D., vice president, global immunology development, AbbVie. "New data being presented on upadacitinib, risankizumab and adalimumab across multiple rheumatic diseases will highlight ...
BioSpace
11/4/2019 AbbVie to Showcase Depth of Immunology Portfolio and Pipeline at the 2019 ACR/ARP Annual Meeting
... the latest research across our recently expanded rheumatology portfolio at this year's meeting, including data that further support our recent FDA approval of RINVOQ," said Marek Honczarenko , M.D., Ph.D., vice president, global immunology development, AbbVie. "New data being presented on upadacitinib, risankizumab and adalimumab across multiple rheumatic diseases will highlight ...
tncontentexchange.com
10/9/2019 AbbVie Announces New Data from its Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress
... clinical experience with HUMIRA, AbbVie recently expanded its dermatology portfolio with the approval of SKYRIZI for patients living with moderate to severe plaque psoriasis," said Marek Honczarenko , MD, PhD, vice president, global immunology development, AbbVie. "The new data presented at EADV will advance the knowledge around new and existing treatments ...
PR Newswire
6/11/2019 New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance
... of Dermatology (WCD) in Milan . "Results show that SKYRIZI has the potential to provide long-term relief from the signs and symptoms of psoriasis," said Marek Honczarenko , M.D., Ph. D., vice president, immunology development, AbbVie. "Our studies demonstrated that SKYRIZI can not only offer complete skin clearance at two years ...
PR Newswire